Anzeige
Erschienen in:
01.06.2015 | Original Article – Clinical Oncology
Differential diagnosis between metastatic and non-metastatic lymph nodes using DW-MRI: a meta-analysis of diagnostic accuracy studies
Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2015
Einloggen, um Zugang zu erhaltenAbstract
Purposes
The purpose of our meta-analysis was to assess the overall diagnostic value of diffusion-weighted magnetic resonance imaging (DW-MRI) in detecting node metastases and investigate whether the apparent diffusion coefficient (ADC) value could be used to discriminate between metastatic and non-metastatic lymph nodes in patients with primary tumors.
Materials and methods
The meta-analysis included a total of 1,748 metastatic and 6,547 non-metastatic lymph nodes from 39 studies, including 8 different tumor types with lymph node metastases.
Results
The pooled sensitivity and specificity of DW-MRI were 0.82 (95 % CI 0.76–0.87) and 0.92 (95 % CI 0.88–0.94), respectively. The positive likelihood ratio (PLR), negative likelihood ratio (NLR), and the area under the curve were 9.8 (95 % CI 6.9–14.0), 0.20 (95 % CI 0.15–0.26) and 0.93 (95 % CI 0.91–0.95), respectively. The probability of 42 % can be viewed as the cutoff pretest probability for DW-MRI to diagnosis lymph node metastases; when the more chance of metastatic increased from 42 % that the pretest probability was estimated, it was more suitable to emphasize on “ruling in,” on the contrary, and when the more chance of metastatic decreased from 42 %, it was more suitable to emphasize on “ruling out.” Furthermore, the mean ADC value of metastatic lymph nodes was significantly lower than that of non-metastatic (P = 0.001).
Conclusions
DW-MRI is useful for differentiation between metastatic and non-metastatic lymph nodes. However, DW-MRI has a moderate diagnostic value for physician’s decision making when PLR and NLR took into consideration, while a superior ability for nodal metastases confirmation, but an inferior ability for ruling out. In the future, large-scale, high-quality trials are necessary to evaluate, respectively, their clinical value in different tumor types with nodal metastases.